Retina

Investigators find approach improved vision and visual fields in some patients.

Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.

Ophthalmology, with its heavy reliance on imaging, is an innovator in the field of artificial intelligence in medicine.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

Study results show that aflibercept-treated eyes are protected.

Retinal imaging tests are providing material to train and test decision support systems.

ADVM-022 offers sharp decrease in treatment burden for patients with nAMD.

Investigators are conducting retinal gene therapy trials that offer potential new treatments for inherited causes of vision loss.

Research teams in various countries are pioneering different methods of data processing and deep-learning AI to create new models of care.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis.

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

A study led by investigators at St. Michael's Hospital of Unity Health Toronto supports pneumatic retinopexy as a primary retinal reattachment technique to achieve better long-term integrity of photoreceptors.

Option has a broader biologic effect for patients.

Worldwide increase in technologies for ophthalmic use is dramatic.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Studies on nurse-led services find a low level of complications among patients.

According to Applied Genetic Technologies Corp., groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.

Dr. Michael Mbagwu speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.